Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs

Reproductive Toxicology

Volumn 29, Issue 2, 2010, Pages 156-163

  Nilsson, M F ^a   Danielsson, C ^b   Skold A C ^c   Johansson, A ^c   Blomgren, B ^c   Wilson, J ^c   Khan, K M ^a   Bengtsson, E ^a   Kultima, K ^a,d   Webster, W S ^e   Danielsson, B R ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASTRAZENECA R AND D   (Sweden)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Astemizole; Embryonic cardiac adverse effects; HERG channel; Hypoxia; IKr; Teratogenicity

Indexed keywords

ASTEMIZOLE; CETIRIZINE; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RESEARCH; EMBRYO; EMBRYO CULTURE; EMBRYOTOXICITY; FEMALE; GESTATION PERIOD; HAND MALFORMATION; HEART ARRHYTHMIA; HEART RATE; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; TERATOGENICITY;

RATTUS;

EID: 77949571010     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.reprotox.2010.01.014     Document Type: Article

References (28)

1. Redfern W.S., Carlsson L., Davis A.S., Lynch W.G., MacKenzie I., Palethorpe S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003, 58(1):32-45.
2. Nerbonne J.M. Studying cardiac arrhythmias in the mouse-a reasonable model for probing mechanisms?. Trends Cardiovasc Med 2004, 14(3):83-93.
3. ICH-E14 International conference of harmonisation of technical requirements for registration of pharmaceuticals for human use: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (E14) 2005, U.S. Food and Drug Administration.
4. ICH-S7B International conference of harmonisation of technical requirements for registration of pharmaceuticals for human use: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (S7B) 2005, U.S. Food and Drug Administration.
5. Davies M.P., An R.H., Doevendans P., Kubalak S., Chien K.R., Kass R.S. Developmental changes in ionic channel activity in the embryonic murine heart. Circ Res 1996, 78(1):15-25.
6. Spence S.G., Vetter C., Hoe C.M. Effects of the class III antiarrhythmic, dofetilide (UK-68,798) on the heart rate of midgestation rat embryos, in vitro. Teratology 1994, 49(4):282-292.
7. Webster W.S., Brown-Woodman P.D., Snow M.D., Danielsson B.R. Teratogenic potential of almokalant, dofetilide, and d-sotalol: drugs with potassium channel blocking activity. Teratology 1996, 53(3):168-175.
8. Webster W.S., Abela D. The effect of hypoxia in development. Birth Defects Res C Embryo Today 2007, 81(3):215-228.
9. Danielsson B.R., Danielsson C., Nilsson M.F. Embryonic cardiac arrhythmia and generation of reactive oxygen species: common teratogenic mechanism for IKr blocking drugs. Reprod Toxicol 2007, 24(1):42-56.
10. Karlsson M., Danielsson B.R., Nilsson M.F., Danielsson C., Webster W.S. New proposals for testing drugs with IKr-blocking activity to determine their teratogenic potential. Curr Pharm Des 2007, 13(29):2979-2988.
11. Taglialatela M., Pannaccione A., Castaldo P., Giorgio G., Zhou Z., January C.T., et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998, 54(1):113-121.
12. NDA19-835 Ceterizine: Oral teratology study in rats 1995, U.S. Food and Drug Administration, [2009-11-27]. http://www.pharmapendium.com/.
13. NDA19-402 Astemizole: approval package 019402 part 1 1985, U.S. Food and Drug Administration, [2009-12-07]. http://www.pharmapendium.com/.
14. New D.A. Whole-embryo culture and the study of mammalian embryos during organogenesis. Biol Rev Camb Philos Soc 1978, 53(1):81-122.
15. Khan K.M., Nilsson M.F., Danielsson B.R., Bengtsson E. Fully automatic heart beat rate determination in digital video recordings of rat embryos. Advances in mass data analysis of images and signals in medicine, biotechnology, chemistry and food industry 2008, 27-37. Springer-Verlag, Berlin Heidelberg. P. Perner, O. Salivetti (Eds.).
16. Arteel G.E., Thurman R.G., Yates J.M., Raleigh J.A. Evidence that hypoxia markers detect oxygen gradients in liver: pimonidazole and retrograde perfusion of rat liver. Br J Cancer 1995, 72(4):889-895.
17. Varia M.A., Calkins-Adams D.P., Rinker L.H., Kennedy A.S., Novotny D.B., Fowler W.C., et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998, 71(2):270-277.
18. d'Argy R., Sperber G.O., Larsson B.S., Ullberg S. Computer-assisted quantification and image processing of whole-body autoradiograms. J Pharmacol Methods 1990, 24(3):165-181.
19. Skold A.C., Danielsson C., Linder B., Danielsson B.R. Teratogenicity of the I(Kr)-blocker cisapride: relation to embryonic cardiac arrhythmia. Reprod Toxicol 2002, 16(4):333-342.
20. Simons F.E., Simons K.J. Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 1999, 36(5):329-352.
21. Hoppu K., Tikanoja T., Tapanainen P., Remes M., Saarenpaa-Heikkila O., Kouvalainen K. Accidental astemizole overdose in young children. Lancet 1991, 338(8766):538-540.
22. Druga A., Nyitray M. Great arteries: Normal development and malformations induced in the rat and mouse. Reprod Toxicol 2008, 26(1):60-61.
23. Chen F., Klitzner T.S., Weiss J.N. Autonomic regulation of calcium cycling in developing embryonic mouse hearts. Cell Calcium 2006, 39(5):375-385.
24. He J.Q., Ma Y., Lee Y., Thomson J.A., Kamp T.J. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circ Res 2003, 93(1):32-39.
25. Pastuszak A., Schick B., D'Alimonte D., Donnenfeld A., Koren G. The safety of astemizole in pregnancy. J Allergy Clin Immunol 1996, 98(4):748-750.
26. Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labeling 2006, European Medicine Agency (EMEA).
27. Danielsson B.R., Skold A.C., Johansson A., Dillner B., Blomgren B. Teratogenicity by the hERG potassium channel blocking drug almokalant: use of hypoxia marker gives evidence for a hypoxia-related mechanism mediated via embryonic arrhythmia. Toxicol Appl Pharmacol 2003, 193(2):168-176.
28. Danielsson B.R., Johansson A., Danielsson C., Azarbayjani F., Blomgren B., Skold A.C. Phenytoin teratogenicity: hypoxia marker and effects on embryonic heart rhythm suggest an hERG-related mechanism. Birth Defects Res A Clin Mol Teratol 2005, 73(3):146-153.